Vertex Pharmaceuticals | VRTX - Interest Expense On Debt



Vertex Pharmaceuticals reported $3.7M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Acadia Pharmaceuticals 0 4.12M Sep/2024
Agios Pharmaceuticals 3.01M 10.05M Dec/2024
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Amgen USD 694M 29M Jun/2025
Arrowhead Research USD 24.38M 2.74M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
Incyte USD 594K 66K Jun/2025
Insmed USD 21.24M 1.5M Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
J&J USD 128M 9M Mar/2025
Merck USD 305M 8M Jun/2025
Moderna USD 1000K 0 Jun/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 289M 19M Jun/2025
Pfizer USD 654M 0 Jun/2025
PTC Therapeutics USD 30.36M 4.03M Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
Sanofi 148M 65M Jun/2025
Sarepta Therapeutics USD 5.23M 725K Jun/2025
Ultragenyx Pharmaceutical 14.04M 1.48M Jun/2025
United Therapeutics USD 7.3M 1.2M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025